CEC Capital advises Zhongkexinyang on 100-million-yuan private financing roundPUBT·2 days ago, 07:09 PM
SHANGHAI SERUM BIO-TECHNOLOGY released its performance for the first three quarters, with a net profit attributable to the parent company of 64.21 million yuan, a year-on-year increase of 2.01%Zhitong·Oct 27, 2025 at 05:20 AM688163+11.45%
Zhitong A-share lock-up release overview | September 11Zhitong·Sep 10, 2025 at 08:01 PM002036-1.31%301110+5.72%
SHANGHAI SERUM BIO-TECHNOLOGY released its semi-annual performance, with a net profit attributable to the parent company of 32.98 million yuan, a year-on-year increase of 2.07%Zhitong·Aug 25, 2025 at 04:09 AM688163+11.45%
SHANGHAI SERUM BIO-TECHNOLOGY: Has not conducted research related to AIDS vaccinesZhitong·Aug 6, 2025 at 02:51 AM688163+11.45%
"Small and Beautiful" Stocks Exposed, 21 Stocks ListedZhitong·May 19, 2025 at 09:24 AM688163+11.45%600883+1.90%
SHANGHAI SERUM BIO-TECHNOLOGY's net profit for the year 2024 is 45.3956 million yuan, a year-on-year increase of 17.08%Zhitong·Feb 25, 2025 at 01:40 AM688163+11.45%
SHANGHAI SERUM BIO-TECHNOLOGY: Appointed Liu Jinbao as Chief Financial OfficerZhitong·Feb 7, 2025 at 03:17 AM688163+11.45%
